IVIG (Cangene)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameIVIG (Cangene)
Drug Alias NameIGIV
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Polyclonal antibodiesBiologics > Blood components
Mechanisms of ActionImmunoglobulin modulators
TargetsImmunoglobulin
Therapy Area/IndicationsImmunologic Deficiency SyndromesPurpura, Thrombocytopenic, Idiopathic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCangene Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCangene Corp
Active IndicationsN/A
Inactive IndicationsImmunologic Deficiency SyndromesPurpura, Thrombocytopenic, Idiopathic

Other Information

ATC CodeN/A
Related LinksN/A